<DOC>
	<DOCNO>NCT02082353</DOCNO>
	<brief_summary>Chronic granulomatous disease ( CGD ) inherit immune system abnormality bone marrow transplantation show curative . However risks transplantation high patient CGD may need undergo high risk procedure . This study determine long term medical condition daily function patient CGD transplant possible , compare result patient undergo transplant .</brief_summary>
	<brief_title>Patients Treated Chronic Granulomatous Disease ( CGD ) Since 1995</brief_title>
	<detailed_description>This multi-center study combine longitudinal cross-sectional evaluation ( retrospectively prospectively ) subject confirm CGD already receive hematopoietic cell transplant ( HCT ) since 1995 receive HCT study period . This study investigate subject benefit HCT , overall outcome CGD patient without transplant . The study aim identify variable contribute best outcome HCT subject CGD .</detailed_description>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Granulomatous Disease , Chronic</mesh_term>
	<mesh_term>Granuloma</mesh_term>
	<criteria>Participant Inclusion Criteria ( Part 1 Longitudinal Analysis ) CGD Patients Undergoing Transplant 1995 Present Birth Year In After 1988 1 . CGD Patients Defined Defective Neutrophil NADPH Oxidase Function Clinical History Consistent CGD Patients must : A functional assay demonstrate abnormal NADPH oxidase function ( see A ) ; AND Clinical history consistent CGD ( see B ) . ************************************************************************* Patients must BOTH `` A '' `` B '' : A . Function : Assays NADPH Oxidase Function I. Dihydrorhodamine ( DHR ) Assay : Blood sample obtain time patient clinically stable critically ill , control sample perform simultaneously indicate qualify assay ; Assay unequivocally demonstrate CGD stimulation index ( SI ) SI &lt; 35 equivalent . Assay report , include mean fluorescence intensity ( MFI ) unstimulated stimulated sample gate strategy , must deidentified provide . OR II . Nitroblue Tetrazolium Oxidation Test ( NBT ) : Diagnostic CGD ( report reduce granulocyte oxidative response ) . Report must deidentified provide . AND B . Clinical History : One More Following : Severe and/or recurrent infection ( liver , perirectal lung abscess ; pneumonia ; adenitis ; osteomyelitis ) due , example , Staphylococcus aureus , Burkholderia sp , Serratia marcescens , nonalbicans Candida sp , Aspergillus sp mold ; Nocardia sp deep tissue infection characteristic CGD Sterile granulomatous disease respiratory , gastrointestinal urogenital tract ; Crohn 's diseaselike colitis A family history consistent either Xlinked autosomal recessive CGD In case either functional assay ( A ) history ( B ) equivocal , one following may use confirm diagnosis CGD : C. Absent significantly reduce expression abnormal size 5 phox component ( gp91 phox , p47 phox , p22 phox , p67phox , p40phox ) NADPH oxidase , either : Western blot Northern blot OR D. Mutation gene encode one 5 phox component ( gp91 phox , p47 phox , p22 phox , p67 phox , p40 phox ) NADPH oxidase predictive decreased absent oxidative burst . ( Nonsense , frameshift , previously describe missense mutation associate CGD ) . Molecular Diagnosis Desirable In addition , molecular diagnosis ( gene sequence expression analysis ) CGD desirable perform possible . 2 . Further Characterization Oxidase Level , Longitudinal Study , Prospective Cohort Patients undergo transplantation study period must characterize oxidasenull oxidase positive level oxidase production either : DHR assay stimulation Index : SI â‰¤ 2.5 classified oxidasenull CGD . Those SI &gt; 2.5 classified oxidase positive CGD . A single validated test accept PIDCGD Review Panel adequate , test two occasion validation desirable . OR Ferricytochrome C reduction assay granulocyte O2 &lt; 2.3 nmoles /106 cells/h classified oxidasenull CGD . A single validated test accept PIDCGD Review Panel adequate , test two occasion validation desirable . OR Genetic sequencing reporting mutation unequivocally associate absent oxidase production . ( e.g . null mutation ) classify oxidasenull CGD ( See discussion Appendix I family history , genotype CGD mutation information apply assign patient lack quantitative oxidase activity measurement residual oxidasenull residual oxidasepositive group ) . 3 . Longitudinal Study , Retrospective Cohort Patients already transplant included regardless whether characterization oxidase level ( genotype/mutation data ) possible . NonTransplanted CGD Patients Birth Year In After 1988 A nontransplant ( conventional therapy ) group CGD subject enrol longitudinal study . The nontransplant subject select potentially eligible ( retrospective ) patient cohort diagnosis CGD treat conventional nontransplant therapy . Participating site enter entire retrospective cohort CGD patient birth year 1988 registration cohort protocol . Baseline nontransplant subject HCT subject purpose compare survival year birth . However , nontransplant subject , many detailed analysis infection autoimmune complication rate assess year precede date last contact . Participant Inclusion Criteria ( Part 2 CrossSectional Analysis ) To participate CrossSectional Analysis , patient must previously enrol Longitudinal Analysis Protocol 6903 . All transplanted subject CrossSectional Analysis survive shall least 3 year followup posttransplant include . Nontransplanted CGD subject become eligible consideration CrossSectional Analysis eligible enrol retrospective cohort Longitudinal Analysis , if/when &gt; 3 year postdiagnosis CGD . Provision write informed consent require inclusion CrossSectional Analysis . Participant Exclusion Criteria ( Longitudinal Cross Sectional Analyses ) Presence primary immunodeficiency syndrome meet clinical laboratory criterion CGD . Rac2 Deficiency Myeloperoxidase Deficiency ( MPO Deficiency ) Glutathione deficiency Leukocyte adhesion deficiency syndrome Nontransplant subject : The exclusion pertain . In addition , nontransplant subject exclude assessment oxidase function available nitroblue tetrazolium ( NBT ) test ( nonquantitative test ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Granulomatous Disease , Chronic</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
</DOC>